Drug intelligence / Profile preview

olverembatinib + inotuzumab ozogamicin

Development stage: Unknown
Lead developer: Ascentage Pharma
Modality: Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Oral, Intravenous

Overview

A combination therapy consisting of olverembatinib, a third-generation tyrosine kinase inhibitor (TKI) effective against the T315I mutation, and inotuzumab ozogamicin, a CD22-directed antibody-drug conjugate. This combination has shown promise in treating relapsed and refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with the T315I mutation, achieving complete molecular response in some patients.

Brand names: Nailike + inotuzumab ozogamicin
Other names: None known for the combination

Targets

CD22 (Cluster of Differentiation 22)ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)

Beyond the preview

Go deeper on olverembatinib + inotuzumab ozogamicin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on olverembatinib + inotuzumab ozogamicin.

Explore the full profile